Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV000170320 | SCV002059482 | uncertain significance | Congenital myasthenic syndrome 17 | 2021-04-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001850415 | SCV002293825 | uncertain significance | Cenani-Lenz syndactyly syndrome; Sclerosteosis 2; Congenital myasthenic syndrome 17 | 2021-05-11 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this variant affects LRP4 protein function (PMID: 24234652). This variant has been observed in individual(s) with congenital myasthenic syndrome (PMID: 24234652). ClinVar contains an entry for this variant (Variation ID: 189820). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glutamic acid with lysine at codon 1233 of the LRP4 protein (p.Glu1233Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. |
OMIM | RCV000170320 | SCV000222707 | pathogenic | Congenital myasthenic syndrome 17 | 2014-04-01 | no assertion criteria provided | literature only |